{"id":"dtg-3tc-abc-elv-cobi-ftc-taf","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypersensitivity reaction (abacavir)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DTG/3TC/ABC (dolutegravir/lamivudine/abacavir) combines an integrase strand transfer inhibitor with two nucleoside reverse transcriptase inhibitors. ELV/COBI/FTC/TAF (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) combines another integrase inhibitor with a pharmacokinetic booster and two nucleotide/nucleoside reverse transcriptase inhibitors. Together, these agents target multiple steps of HIV replication to achieve viral suppression.","oneSentence":"This is a fixed-dose combination of two antiretroviral regimens that inhibit HIV reverse transcriptase and integrase to suppress viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:32:32.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve or treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT03067285","phase":"PHASE4","title":"A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2017-09-08","conditions":"HIV Infections","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DTG/3TC/ABC + ELV/COBI/FTC/TAF","genericName":"DTG/3TC/ABC + ELV/COBI/FTC/TAF","companyName":"Fundacion SEIMC-GESIDA","companyId":"fundacion-seimc-gesida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a fixed-dose combination of two antiretroviral regimens that inhibit HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve or treatment-experienced adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}